



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	Application Number	09/774,171
	Filing Date	February 1, 2001
	First Named Inventor	DICKINSON
	Group Art Unit	1615
	Examiner Name	Spear, James M.
	Attorney Docket Number	2955-134
Title: PHARMACEUTICAL COMPOSITIONS COMPRISING IBUPROFEN AND DOMPERIDONE		

TERMINAL DISCLAIMER

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The owner, The Boots Company PLC., of one hundred percent (100%) interest in the instant application, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156, of any patent granted on U.S. Application No. 10/922,828. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the above-identified application and any patent issued thereon are commonly owned. This agreement runs with any patent granted on the instant application, and is binding upon grantees, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 of any of the above-identified patents or of

any patent granted on the above-identified applications, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: (1) expires for failure to pay a maintenance fee, (2) is held unenforceable, (3) is found invalid by a court of competent jurisdiction, (4) is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, (5) has all claims canceled by a reexamination certificate, (6) is reissued, or (7) is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Terminal disclaimer fee under 37 CFR 1.20(d) is included.

X 

Michael John Oliver, Company Secretary

2955-134.1d.wpd

APPROVED FOR SIGNATURE
S. A. HEARSON 